Cisplatin and docetaxel induction chemotherapy results Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005
Pulmonary toxicity during chemotherapy with etopiside and carboplatin Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003
A randomised phase III trial by the European lung cancer working party comparing sequential administration of cisplatin-based chemotherapy followed by a taxan and a cisplatin-based standard chemotherapy, with the use of taxan as salvage treatment Source: Eur Respir J 2006; 28: Suppl. 50, 833s Year: 2006
Effectiveness of oral metronomic Vinorelbine versus Docetaxel as second-line treatment in Non-Small Cell Lung Cancer patients in real life Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020
Multicentre phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited stage small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 394s Year: 2001
Consolidation maintenance oral vinorelbine following concurrent chemoradiation of intravenous vinorelbine and cisplatin in patients with unresectable stage III non-small cell lung cancer Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015
Radiation oncology perceptive: radiotherapist considerations for concurrent chemo-RT Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019
Evaluation of the efficacy of cisplatin–etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC Source: ERJ Open Res, 3 (1) 00128-2016; 10.1183/23120541.00128-2016 Year: 2017
A phase II trial of lipoplatin and gemcitabine in patients with NSCLC previously treated with platinum-based chemotherapy Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016
Effectivity of chemotherapy regimen included carboplatin, ifosfamide, etoposide with or without adding interferon alpha 2a in treatment of patients with small cell lung carcinoma Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005
Combination of oral and parenteral vinorelbine with cisplatin or carboplatin in adjuvant chemotherapy of nonsmall cell lung cancer - SWITCH study Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015
Concurrent chemoradiotherapy with carboplatin and paclitaxel followed by consolidation chemotherapy with vinorelbine for locally advanced inoperable nonsmall-cell lung cancer: A multiinstitutional phase II study Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Single agent gemcitabine or docetaxel in the second-line therapy for patients with non-small cell lung cancer previously treated with platin-based chemotherapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013
Efficacy of induction chemotherapy and following simultaneous radiochemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (Stage IIIA/IIIB): update of CT/RT 99/97 Source: Annual Congress 2004 - Management of lung cancer and innovative therapies Year: 2004
Weekly chemotherapy with cisplatin/paclitaxel in the front-line treatment of NSCLC: a phase II study Source: Eur Respir J 2004; 24: Suppl. 48, 672s Year: 2004
Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 301s Year: 2004
Antituberculosis chemotherapy toxicity reduction Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012
TTF 1- expression and pemetrexed based chemotherapy. A retrospective analysis Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015
Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy Source: Eur Respir J 2001; 18: 243-245 Year: 2001
Phase I trial of pemetrexed, carboplatin and sorafenib as first-line treatment in patients with metastatic NSCLC Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010